U.S. Markets closed

Welldoc’s BlueStar® Digital Therapeutic Wins Digital Diabetes Congress 2019 Mobile App Contest

Anand Iyer, PhD, Chief Strategy Officer, Accepts “Established App” Award at Diabetes Technology Society’s Digital Diabetes Congress

COLUMBIA, Md., May 15, 2019 (GLOBE NEWSWIRE) -- Today, Welldoc announced that the Diabetes Technology Society has selected BlueStar digital therapeutic as the winner of the Digital Diabetes Congress 2019 Mobile App Contest, in the category of “Established App.” Dr. Anand Iyer, Welldoc Chief Strategy Officer, accepted the award on May 14 on behalf of the Welldoc’s team work on the first FDA-cleared digital therapeutic for individuals with type 2 diabetes.

The Diabetes Technology Society (DTS) and Sansum Diabetes Research Institute’s Digital Diabetes Congress meeting is held annually in San Francisco. Clinicians, scientists, app developers, regulators, and entrepreneurs attend with a similar mission to bring “digital health forward in mainstream care.”

“It’s a true honor for Welldoc’s work to be recognized by the Diabetes Technology Society through this award,” said Dr. Iyer. “We value our relationship with DTS as the society represents professionals like us who are passionate about advancing technology to improve the lives of people with diabetes.”

The award-winning BlueStar engages people with diabetes and delivers precision, real-time feedback to help improve long-term health. With seamless integration to blood glucose meters, pharmacies, labs, activity and fitness trackers, BlueStar aggregates the data to deliver actionable insights for the user’s care team to optimize care.

The Diabetes Technology Society (DTS) is a nonprofit organization established in 2001. DTS is committed to promoting development and use of technology in the fight against diabetes. DTS hosts three scientific conferences each year where several thousand scientists and researchers participate from more than 25 countries.

About Welldoc
Welldoc® is a leading digital therapeutic company revolutionizing chronic disease management to help transform lives. The Company’s groundbreaking technology helps guide individuals through the complicated journey of living with chronic diseases, with a goal of helping them self-manage their conditions, while connecting them to their own healthcare team. By utilizing Welldoc’s digital therapeutic solutions, payers, employers and healthcare systems can streamline their resources by focusing on a digital health solution to help better manage their populations living with multiple and costly chronic diseases. Welldoc is based on a life science business model—having conducted multiple randomized clinical trials resulting in more than 40 peer-reviewed publications. IBM Watson Health™ conducted an innovative economic analysis for Welldoc using the MarketScan® Commercial Claims and Encounters Database and the MarketScan® Medicare Supplemental and Coordination of Benefits Database demonstrating an opportunity to save a range of $254 to $271 per user per month with the use of the flagship BlueStar® digital therapeutic. Welldoc has a solid foundation in the development of solutions for the management of diabetes and is rapidly creating other chronic disease solutions. This year, Welldoc secured a patent for the Software Engine Technology that powers BlueStar. Notably, this is the Company’s tenth issued patent. For more information, visit www.welldoc.com.

Media Contact:

Michelle Pelszynski
Welldoc
Tel: +1 443.692.3129
Email: mpelszynski@welldoc.com